Fintel reports that on December 8, 2023, Citigroup initiated coverage of Allogene Therapeutics (NASDAQ:ALLO) with a Buy recommendation.
Analyst Price Forecast Suggests 463.55% Upside
As of November 27, 2023, the average one-year price target for Allogene Therapeutics is 14.20. The forecasts range from a low of 4.54 to a high of $36.75. The average price target represents an increase of 463.55% from its latest reported closing price of 2.52.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Allogene Therapeutics is 4MM, an increase of 2,042.47%. The projected annual non-GAAP EPS is -2.83.
What is the Fund Sentiment?
There are 391 funds or institutions reporting positions in Allogene Therapeutics. This is an increase of 9 owner(s) or 2.36% in the last quarter. Average portfolio weight of all funds dedicated to ALLO is 0.08%, a decrease of 16.69%. Total shares owned by institutions decreased in the last three months by 0.67% to 140,889K shares. 
The put/call ratio of ALLO is 0.43, indicating a bullish outlook.
What are Other Shareholders Doing?
Tpg Gp A holds 18,716K shares representing 11.12% ownership of the company. No change in the last quarter.
Jpmorgan Chase holds 6,911K shares representing 4.11% ownership of the company. In it's prior filing, the firm reported owning 6,134K shares, representing an increase of 11.24%. The firm decreased its portfolio allocation in ALLO by 27.04% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 6,301K shares representing 3.74% ownership of the company. In it's prior filing, the firm reported owning 6,591K shares, representing a decrease of 4.59%. The firm decreased its portfolio allocation in ALLO by 27.82% over the last quarter.
Woodline Partners holds 5,314K shares representing 3.16% ownership of the company. In it's prior filing, the firm reported owning 5,314K shares, representing an increase of 0.01%. The firm decreased its portfolio allocation in ALLO by 36.91% over the last quarter.
Primecap Management holds 5,284K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 5,637K shares, representing a decrease of 6.67%. The firm decreased its portfolio allocation in ALLO by 39.59% over the last quarter.
Allogene Therapeutics Background Information
(This description is provided by the company.)
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
